How US-Based Companies Can Secure An EU Manufacturing And Importation Authorisation (MIA)

EU Manufacturing and Importation Authorisation (MIA) Authorisation required for companies manufacturing or importing medicinal products in the EU. For US-based manufacturers, contract manufacturers and distributors aiming to supply the EU market, obtaining or working with an EU MIA is a critical compliance step that requires planning, documentation and often collaboration with an EU-based licence holder or importer.

US companies should view the MIA as part licence, part evidence-gathering process: European authorities must be satisfied that the EU-based site or importer they deal with meets GMP and regulatory requirements. While a US company cannot directly receive a licence for a non-EU site, it can support EU partners (importers or contract manufacturers) by providing complete GMP documentation, quality agreements and access for inspections.

Options For US Companies

• Use An EU-Based Importer: A local importer holds the MIA and is responsible for verifying the US manufacturing site's GMP compliance.
• Contract With An EU CMO: Manufacture within the EU under a site that already holds an MIA; this avoids import authorisation complexity but may add costs and lead times.
• Obtain Recognition Documents: Provide GMP certificates, inspection reports and quality agreements so an EU partner can demonstrate compliance to their competent authority.

Documentation US Manufacturers Must Provide

EU authorities expect objective evidence that the non-EU manufacturer operates to standards equivalent to EU GMP. Commonly required documents include a current GMP certificate (if available), recent inspection reports, a complete site master file, validated manufacturing and cleaning records, stability data and access to personnel for regulatory questions. The EU importer should also hold a suitable quality agreement that defines responsibilities for batch release, recall actions and pharmacovigilance.

Inspection And Recognition

European regulators may accept GMP inspection reports from trusted partners or third-country inspection schemes, but acceptance varies. US manufacturers frequently undergo inspections by EU inspectors or rely on existing US FDA inspection reports. Some Member States require an EU inspection or exchange of information before granting an import authorisation; others accept an up-to-date FDA inspection report plus supporting documentation.

Key Contract And Quality Considerations

• Quality Agreement: Define responsibilities for GMP compliance, batch certification, deviations, recalls, complaints and pharmacovigilance.
• Documentation Access: Commit to providing inspection access, batch records and certification documentation to the EU partner and, where required, to regulators.
• Logistics And Import Controls: Ensure cold chain, release sampling and customs processes are mapped and aligned with the importer’s MIA conditions.

Practical Example For A US API Supplier

A US API manufacturer supplies active substance to a Portuguese finished product manufacturer that holds an MIA. The US supplier provides a current GMP certificate, a supplier qualification dossier, and allows the Portuguese site to audit its operations. The Portuguese manufacturer includes the US supplier in their supplier management program and lists the supplier in their MIA application as an approved supplier; the Portuguese competent authority reviews and accepts the evidence during their assessment.

Common Pitfalls And How To Avoid Them

• Incomplete Dossiers: Missing validation or stability data delays MIA processing — establish a complete site master file before starting the application.
• Poorly Defined Agreements: Ambiguous responsibilities for batch release or recall create regulatory risk — write clear quality agreements.
• Underestimating Inspection Needs: Be prepared for EU inspections and invest in gap remediation where EU and US GMP expectations differ.

Practical Steps To Prepare

• Conduct A GMP Gap Assessment: Compare your systems to EudraLex Volume 4 and PIC/S standards.
• Engage An EU Representative: Work with an experienced EU importer, regulatory consultant or legal adviser who understands Member State specifics.
• Organize Records For Inspection: Keep validation, batch and training records readily available and in English (or provide translations when required).

In short, the EU Manufacturing and Importation Authorisation (MIA) is the instrument that allows medicinal products to be manufactured or imported into the EU legally. For US companies, success hinges on supplying robust GMP evidence, clear contractual arrangements with EU partners and readiness for inspections — practical steps that turn regulatory requirements into reliable market access.